P&G paid $3.8 billion for permission to speak clinically

P&G is acquiring Thorne from L Catterton for $3.8 billion, building out its Personal Health Care division alongside brands such as Metamucil, Align and New Chapter, in what is now a run of high-profile supplement acquisitions this year. Read as a portfolio move, it is unremarkable. Read as a capability move, it is the more instructive deal of the month. Thorne is not a shelf brand awaiting distribution; it is a practitioner-channel business with clinical positioning, and it has already built GLP-1-specific supplement protocols targeting lean mass, protein intake and micronutrient gaps, the specialist model we describe in this week's whitepaper. That is the point. Rapid weight reduction creates genuinely new physiological needs around muscle preservation, nutrient density and hydration, and credibility in that conversation cannot be manufactured with a claim on a pack. It is either acquired or earned slowly, over years. Most large consumer-health portfolios currently have neither, and the window in which credibility can still be bought at this price is closing. (Nutritional Outlook)